BioCentury
ARTICLE | Company News

Court of Appeals denies Acorda's injunction for Ampyra

July 25, 2018 10:36 PM UTC

Acorda Therapeutics Inc. (NASDAQ:ACOR) lost $4.15 (14%) to $24.55 on Wednesday after the U.S. Court of Appeals for the Federal Circuit denied the company's injunction to prevent generic competition for Ampyra dalfampridine from entering the market while an appeal of a district court ruling is ongoing.

In 2017, the U.S. District Court for the District of Delaware ruled that four of five patents covering the multiple sclerosis drug were invalid on grounds of obviousness. The remaining patent, U.S. Patent No. 5,540,938, was deemed valid but expires in July...